SEARCH:   Advanced

Blood, 15 November 2005, Vol. 106, No. 10, pp. 3383-3385. Prepublished online as a Blood First Edition Paper on August 9, 2005; DOI 10.1182/blood-2005-04-1603. This Article Full Text (PDF) All Versions of this Article: 2005-04-1603v1 106/10/3383    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Moskowitz, C. H Articles by Teruya-Feldstein, J. Search for Related Content PubMed PubMed Citation Articles by Moskowitz, C. H Articles by Teruya-Feldstein, J. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 20, 2005 Accepted July 25, 2005 Cell of origin, germinal center vs non-germinal center as determined by immunohistochemistry on tissue microarray, does not correlate with outcome in relapsed or primary refractory DLBCL Craig H Moskowitz*, Andrew D Zelenetz, Tarun Kewalramani, Paul Hamlin, Simone Lessac-Chenen, Jane D Houldsworth, Adam Olshen, Raju Chaganti, Stephen Nimer, and Julie Teruya-Feldstein Lymphoma and Hematology Services of the Division of Hematological Oncology, Department of Medicine, Memorial Sloan Kettering, NY, NY, USA Department of Pathology, Memorial Sloan Kettering Cancer Center, NY, NY, USA * Corresponding author; email: moskowic{at}mskcc.org. A number of prognostic factors affect outcome in patients with relapsed or primary refractory DLBCL such as refractory disease, and the second-line age-adjusted international prognostic index. We utilized tissue microarray to evaluate cell of origin, and several pathologic markers of outcome, on the repeat biopsy specimen of 88 transplant-eligible patients undergoing ICE second-line chemotherapy (SLT) followed by high dose therapy (HDT) and ASCT to see if they were prognostic in the salvage setting. When patients first present with DLBCL, cell of origin as determined by expression microarray analysis or immunohistochemistry (IHC) predicts for event-free survival (EFS). However, we saw no difference in response to SLT, HDT, event-free or overall survival based upon the cell of origin or any of the common pathologic markers examined. Conclusion: the cell of origin as determined by IHC does not predict outcome in transplant-eligible patients with relapsed or primary refractory DLBCL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. Aster and J. Kutok Complexity Made Simple in Diffuse Large B-Cell Lymphoma Clin. Cancer Res., September 1, 2009; 15(17): 5291 - 5293. [Abstract] [Full Text] [PDF] D de Jong, W Xie, A Rosenwald, M Chhanabhai, P Gaulard, W Klapper, A Lee, B Sander, C Thorns, E Campo, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) J. Clin. Pathol., February 1, 2009; 62(2): 128 - 138. [Abstract] [Full Text] [PDF] K. Amara, M. Trimeche, S. Ziadi, A. Laatiri, M. Hachana, and S. Korbi Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas Ann. Onc., October 1, 2008; 19(10): 1774 - 1786. [Abstract] [Full Text] [PDF] S. Nakamura, H. Ye, C. M. Bacon, A. Goatly, H. Liu, L. Kerr, A. H. Banham, B. Streubel, T. Yao, M. Tsuneyoshi, et al. Translocations Involving the Immunoglobulin Heavy Chain Gene Locus Predict Better Survival in Gastric Diffuse Large B-Cell Lymphoma Clin. Cancer Res., May 15, 2008; 14(10): 3002 - 3010. [Abstract] [Full Text] [PDF] J. Dupuis, P. Gaulard, F. Hemery, E. Itti, C. Gisselbrecht, A. Rahmouni, C. Copie-Bergman, J. Briere, T. E. Gnaoui, I. Gaillard, et al. Respective prognostic values of germinal center phenotype and early 18fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma Haematologica, June 1, 2007; 92(6): 778 - 783. [Abstract] [Full Text] [PDF] H. Nyman, M. Adde, M.-L. Karjalainen-Lindsberg, M. Taskinen, M. Berglund, R.-M. Amini, C. Blomqvist, G. Enblad, and S. Leppa Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy Blood, June 1, 2007; 109(11): 4930 - 4935. [Abstract] [Full Text] [PDF] D. de Jong, A. Rosenwald, M. Chhanabhai, P. Gaulard, W. Klapper, A. Lee, B. Sander, C. Thorns, E. Campo, T. Molina, et al. Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications--A Study From the Lunenburg Lymphoma Biomarker Consortium J. Clin. Oncol., March 1, 2007; 25(7): 805 - 812. [Abstract] [Full Text] [PDF] G. W. van Imhoff, E.-J. G. Boerma, B. van der Holt, E. Schuuring, L. F. Verdonck, H. C. Kluin-Nelemans, and P. M. Kluin Prognostic Impact of Germinal Center-Associated Proteins and Chromosomal Breakpoints in Poor-Risk Diffuse Large B-Cell Lymphoma J. Clin. Oncol., September 1, 2006; 24(25): 4135 - 4142. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020